CCL18 and breast carcinoma: In in vitro experiments, the group showed that the invasiveness of MDA-MB-231 cells and primary breast cancer cells was enhanced equally by the addition of recombinant CCL18 and coculture with TAMs, whereas the addition of anti-CCL18 and CCL18-siRNAs reduced the number of invasive cancer cells.